Background: Recent trials have shown hydroxyethyl starch (HES) solutions increase the risk of acute kidney injury (AKI) in critically ill patients. It is uncertain whether these adverse effects also affect surgical patients. We sought to determine the renal safety of modern tetrastarch (6% HES 130/0.4) use in cardiac surgical patients. Methods: In this multicentre prospective cohort study, 1058 consecutive patients who underwent cardiac surgery from 15th September 2012 to 15th December 2012 were recruited in 23 Spanish hospitals. Results: We identified 350 patients (33%) administered 6% HES 130/0.4 intraoperatively and postoperatively, and 377 (36%) experienced postoperative AKI (AKI Network criteria). In-hospital death occurred in 45 (4.2%) patients. Patients in the non-HES group had higher Euroscore and more comorbidities including unstable angina, preoperative cardiogenic shock, preoperative intra-aortic balloon pump use, peripheral arterial disease, and pulmonary hypertension. The non-HES group received more intraoperative vasopressors and had longer cardiopulmonary bypass times. After multivariable risk-adjustment, 6% HES 130/0.4 use was not associated with significantly increased risks of AKI (adjusted odds ratio 1.01, 95% CI 0.71-1.46, P=0.91). These results were confirmed by propensity score-matched pairs analyses. Conclusions: The intraoperative and postoperative use of modern hydroxyethyl starch 6% HES 130/0.4 was not associated with increased risks of AKI and dialysis after cardiac surgery in our multicentre cohort.
Approximately one million cardiac surgery procedures are undertaken every year worldwide. 1 Optimization of fluid status in the cardiac surgical patient is an important management objective of anaesthetists and critical care clinicians in the perioperative period. Appropriate volume restoration can help maximize cardiac output, systemic perfusion pressures, and microcirculatory flow. There is no clear consensus about the optimal type of fluid.
Colloids are often used in the fluid resuscitation of surgical patients, in part because of potential benefits such as faster haemodynamic stabilization 2 and presumed reduced risk of oedema formation. For many decades, hydroxyethyl starches (HES) have been used as one of several standard colloid solutions for volume replacement therapy. Recently, two randomized controlled trials in the intensive care setting-the CHEST 3 and 6S trial 4 -found that tetrastarches increased the use of dialysis and blood transfusion products; furthermore, the 6S trial which focused on patients with severe sepsis, found an 8% higher 90-day mortality associated with tetrastarches. 4 Routine cardiac surgery patients, however, were excluded from these trials. The safety of HES may differ when used in relatively healthy people rather than septic patients, because sepsis affects vascular endothelium, 5 altering distribution of large molecules. 6 Data on the intraoperative and postoperative use of modern tetrastarch products in the cardiac surgical setting are limited. Given the uncertain generalizability of data from critically ill patients to the surgical population, we conducted a multicentre prospective cohort study to determine the association of intraoperative and postoperative modern tetrastarch (6% HES 130/0.4) use, with postoperative renal function in patients undergoing cardiac surgery.
Methods

Study design
This study was a multicentre prospective cohort study at 23 cardiac surgery centres in Spain. The study cohort included all consecutive patients aged 18 yr or older (n=1058) who underwent cardiac surgery between 15th September 2012 and 15th December 2012. All cardiac surgery procedures were included except for heart transplantation surgery. Patients with preoperative dialysis requirements were excluded. Data from each site was sent to a central database. The study was in compliance with the Declaration of Helsinki and reviewed and approved by each of the institution's Ethics Committee, and individual consent was waived. The cohort was divided into two groups, namely patients who received (n=350) or did not receive (n=708) 6% HES 130/0.4 intraoperatively and postoperatively. All sites used only 6% 130/0.4 as their colloid.
Outcomes
The primary endpoint was AKI as defined by the Acute Kidney Injury Network (AKIN) criteria. 7 Both the creatinine and urine output components of these criteria were applied. Urine output was measured at 6, 12, 24 and 48 h after surgery. The secondary outcome was the need for renal replacement therapy (RRT).
Statistical analysis
All analyses were performed using STATA version 13.0 (StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP). Statistical significance was defined by a 2-sided P-value less than 0.05. The Shapiro-Wilk test was used to determine whether variables were normally distributed. Unadjusted differences between treatment and control arms were then calculated using the Mann-Whitney U-test (continuous variables) and Fisher's exact test (categorical variables).
The adjusted association between 6%-HES and postoperative outcomes of interest was then estimated using multivariable logistic regression models that included the following covariates: age, sex, BMI, baseline left ventricle ejection fraction, preoperative cardiogenic shock, preoperative intra-aortic balloon pump use, unstable angina, chronic kidney disease, pulmonary hypertension, hypertension, baseline haemoglobin, chronic obstructive pulmonary disease, diabetes mellitus, surgery type, redo cardiac surgery, urgent surgery, peripheral arterial disease, hospital site, Euroscore, Cleveland Score, loop diuretic use within 48 h before surgery, intraoperative use of vasopressors, CPB time, minimum intraoperative haemoglobin, intraoperative red cell transfusion, use of noradrenaline or adrenaline, use of postoperative intra-aortic balloon pump (IABP) and re-intervention in 48 h postoperatively. Results were expressed as adjusted odds ratios (ORs) with 95% confidence intervals (CI). We evaluated the performance of these regression models using several different approaches. First, internal validation was conducted using bootstrap resampling (1000 replications). Second, the variance inflation factor was used to identify any important multicollinearity. Third, we evaluated model discrimination using the c-statistic and model calibration using the Hosmer-Lemeshow statistic. In a sensitivity analysis, we repeated the regression analyses while excluding covariates that might be in the causal pathway between HES use and AKI (e.g. blood product transfusion, nadir haemoglobin).
To confirm these regression-based analyses, we also conducted a complementary propensity score-matched pairs analysis.
Results
Descriptive data
The cohort included 1058 consecutive patients who underwent cardiac surgery.
Of the cohort, 350 (33%) were exposed to 6% HES 130/0.4 intraoperatively and postoperatively. Postoperative AKI occurred in 377 patients (36%), which was associated with a 15-fold increase in-hospital mortality (10.6% vs 0.7%; P<0.001).
There were several baseline differences between the HES and non-HES study arms.
Patients in the non-HES group had higher Euroscores and greater burden of comorbidity (e.g. unstable angina, preoperative cardiogenic shock, preoperative use of IABP, peripheral arterial disease, pulmonary hypertension). Intraoperatively they were more likely to receive vasopressors. Patients in the non-HES group were less likely to undergo isolated CABG or off-pump CABG, and more likely to undergo valve surgery ( Table 1 ). The
Editor's key points
• The perioperative safety and effectiveness of modern starch solutions is in doubt.
• Important differences between critically ill patients and those undergoing surgery.
• Administration of small volumes of a starch solution may or may not lead to kidney injury.
• This study could not identify an increase in renal risk with a tetrastarch in cardiac surgery. 
P=0.42).
The propensity score-matched groups are presented in Table 4 . Propensity score matching confirmed these findings (OR 1.02, 95% CI: 0.94-1.12, P=0.51). In a sensitivity analysis that 
Renal replacement therapy
The overall incidence of RRT was 3.5% (n=37). Although RRT is included in AKI stage III based on AKIN consensus definition, we performed univariate analysis and propensity score matching to look specifically for the RRT outcome. As there were only 37 RRT events, we conducted risk-adjusted analyses using propensity score matching alone (as opposed to regression modeling).
No difference between groups were found in the unadjusted analysis (OR 1.09 [95% CI: 0.55-2.18], P=0.78) ( Table 3 ). The propensity score analyses showed that intraoperative and postoperative use of modern HES (vs non-HES) was not associated with significant differences in risk of RRT (OR 0.99, 95% CI: 0.63-1.30, P=0.63).
Discussion
In this multicentre cohort study of 1058 consecutive patients who underwent cardiac surgery, we observed that the use of modern tetrastarches was not associated with significantly higher rate of AKI or RRT. Two adjusted analyses confirmed the results of the unadjusted analysis. Our observations are largely consistent with recent meta-analyses evaluating the effect of modern tetrastarches on renal function, specifically in the surgical population. [8] [9] [10] In their review of 39 trials on 3389 surgical patients, Van der Linden and colleagues 9 concluded that the use of tetrastarches during surgery was not associated with a higher rate of AKI or RRT. Twenty-one trials (n=1974) included in the review were cardiac surgical patients. A second review by Weiskopf and colleagues 11 confirmed these findings in the cardiac surgery population. Martin and colleagues 8 in their metaanalysis on 17 randomized studies (n=1230), also found that the use of modern tetrastarches in the surgical population was not associated with AKI. Nine trials (n=873) included in the meta-analysis were cardiac surgical patients. Guilles and colleagues 10 focused only on surgical patients including cardiac and non-cardiac surgery, and found no difference in in-hospital mortality, AKI and use of RRT with the use of 6% HES solution. Eleven trials (n=868) out of 19 RCT included in the meta-analysis were cardiac surgical patients. We consider our results may add some data in this specific context. Notably, a recent prospective single-centre cohort study in cardiac surgery patients did find that intraoperative and postoperative use of HES was associated with a higher rate of AKI and RRT. 12 Nonetheless, individuals in the HES-arm of the study all received aprotinin, which is a well-known risk factor for AKI. [13] [14] [15] In addition, the analysis did not adjust for several important risk factors for AKI, such as chronic obstructive pulmonary disease, and left ventricle ejection fraction. In contrast to our findings in cardiac surgery patients, randomized controlled trials 3 4 and meta-analyses 16 in ICU patients have found renal adverse effects with tetrastarches. However, there are issues to consider when evaluating how generalizable these results are. Many patients in these trials were septic, and it is unclear whether the harm seen in these trials applies to healthier cardiac surgery patients. Patients in some trials -6S -received much larger amounts of colloids than would be seen in usual clinical practice. As the cardiac surgical patient population and the septic patients are likely to differ, the safety of HES may differ when used in the cardiac surgery setting rather than in septic patients. 17 18 For example, Tassani and colleagues   19 showed that the cardiopulmonary bypass-induced inflammatory response does not result in an alteration of protein distribution. A capillary leak syndrome associated with CPB in elective CABG operations was not observed. In addition, Butler and colleagues 20 showed that the systemic inflammatory response from cardiac surgery and the septic patients seems to differ. These physiological differences may, in part, explain the contrast between harm associated with HES in critically ill patients vs generally neutral findings in cardiac surgical patients. Notably, our results, while reassuring, do not definitively prove the safety of using HES in cardiac surgical patients. Further similar research is needed in other settings and datasets to confirm these present findings. In addition, even if HES is found to be safe in cardiac surgery, its additional cost entails that HES also provide specific clinical benefits to justify its use in perioperative care. There are some limited data showing potential benefits from HES 130/0.4, albeit principally in pre-clinical studies. For example, HES 130/0.4 may be more advantageous for maintenance of tissue oxygenation during progressive anaemia in pigs. 21 In addition, Konrad and colleagues 22 showed that HES 130/0.4 is associated with less tissue oedema formation and increased renal microvascular oxygenation during acute normovolaemic haemodilution in pigs. In an experimental acute lung injury model in non-septic pigs, Silva and colleagues 23 showed that intravascular volume expansion with HES 130/0.4 after major haemorrhage yielded less lung injury and kidney injury than Ringer's acetate or gelatin-polysuccinate. With respect to human clinical data, a small RCT of 30 cardiac surgery patients with normal preoperative renal function, found that crystalloid-induced increases in GFR were associated with impaired renal oxygenation, a problem that was not seen with HES. 24 More high-quality research in humans clearly remains needed, to identify important clinical benefits of using HES in cardiac surgery. Our study has several limitations that should be considered. First, there were important baseline differences between the HES and non-HES groups. We addressed this issue by adjusting for these differences with two different methods -regression modelling and propensity score analyses. Second, our cohort experienced a high incidence of AKI. Nonetheless, this rate is consistent with the literature and the mild definition used. 25 Notably, the rate of RRT in our study is largely consistent with the literature. Notably, the point estimates for effects on both AKI ( propensity score adjusted OR 1.02) and RRT ( propensity score adjusted OR 0.99) were consistent in that HES was not associated with poor renal outcomes. Third, the 95% CIs for our adjusted estimates were somewhat wide, and do not exclude a 25-35% increase in the odds of AKI. Thus, while the point estimate is reassuring (adj. OR ∼ 1), more studies still remain needed to confirm the renal safety of HES in cardiac surgical patients. Fourth, as with most observational studies, we cannot exclude the possibility of residual unmeasured confounding. Fifth, our data sources did not capture the amount of 6% HES 130/0.4 given, but in clinical practice, less than 1500 ml was almost always given. The strengths of this study include its pragmatic real-world cardiac surgery population including 23 hospitals, detailed data collection, use of AKI consensus definition based on AKIN criteria and risk adjustment using the Cleveland score -a clinical risk score to specifically predict renal outcomes in the cardiac surgical setting. We also used two different methods of adjustment by regression modeling and propensity score analyses.
In conclusion, intraoperative and postoperative use of modern tetrastarches was not associated with increased risks of AKI and RRT after cardiac surgery in this multicentre cohort. However, given the wide 95% CI, our study does not exclude potential
